Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H.pylori: A prospective study

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 5, 2013, Pages 527-529

  Ergül, Bilal ^a   Koçak, Erdem ^a   Taş, Adnan ^a   Filik, Levent ^a   Köklü, Seyfettin ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; CITRIC ACID; LANSOPRAZOLE; MOXIFLOXACIN; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PEPTIC ULCER; PROSPECTIVE STUDY; PRURITUS; RASH; UREA BREATH TEST;

ADULT; AGED; ANTACIDS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUINOLINES; TETRACYCLINE; YOUNG ADULT;

EID: 84886948774     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.10.014     Document Type: Article

References (19)

1. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56:772-781.
2. Megraud F., Coenen S., Versporten A., Kist M., Lopez-Brea M., Hirschl A.M., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62(1):34-42.
3. Onder G., Aydin A., Akarca U., Tekin F., Ozutemiz O., Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007, 41(8):747-750.
4. Kadayifci A., Buyukhatipoglu H., Cemil Savas M., Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10years. Clin Ther 2006, 28(11):1960-1966.
5. Nista E.C., Candelli M., Zocco M.A., Cazzato I.A., Cremonini F., Ojetti V., et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005, 21(10):1241-1247.
6. Yalin Kilic Z.M., Köksal S.A., Cakal B., et al. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 2008, 53:3133-3137.
7. Sun Q., Liang X., Zheng Q., Liu W., Xiao S., Gu W., et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010, 15(3):233-238.
8. Malfertheiner P., Bazzoli F., Delchier J.C., Celiñski K., Giguère M., Rivière M., et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3trial. Lancet 2011, 377(9769):905-913.
9. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012, 61(5):646-664.
10. Taş A., Akbal E., Koçak E., Köklü S. Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study. Helicobacter 2011, 16(1):52-54.
11. Miehlke S., Schneider-Brachert W., Kirsch C., Morgner A., Madisch A., Kuhlisch E., et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008, 13(1):69-74.
12. Sacco F., Spezzaferro M., Amitrano M., Grossi L., Manzoli L., Marzio L. Efficacy of four different moxifloxacin-based triple therapies for first-line H.pylori treatment. Dig Liver Dis 2010, 42(2):110-114.
13. Copeman M., Matuz J., Leonard A.J., Pearson J.P., Dettmar P.W., Allen A. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J Gastroenterol Hepatol 1994, 9(Suppl.1):S55-S59.
14. Bagchi D., Carryl O.R., Tran M.X., Krohn R.L., Bagchi D.J., Garg A., et al. Stress, diet and alcohol-induced oxidative gastrointestinal mucosal injury in rats and protection by bismuth subsalicylate. J Appl Toxicol 1998, 18(1):3-13.
15. Weusten B.L., Sicking P.J., Otten H.W., Smout A.J., Otten M.H. Relief of dyspeptic symptoms by colloidal bismuth subcitrate in Helicobacter-negative and -positive patients: results of a study in general practice. Neth J Med 2000, 57(6):209-214.
16. Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 2000, 14:885-889.
17. Demir M., Ataseven H. The effects of sequential treatment as a first-line therapy for Helicobacter pylori eradication. Turk J Med Sci 2011, 41(3):427-433.
18. Özden A., Seven G., Bektaş M. Effectiveness of different treatment regimens in Helicobacter pylori eradication: ten-year experience of a single institution. Turk J Gastroenterol 2010, 21(3):218-223.
19. Polat Z., Kadayifci A., Kantarcioglu M., Ozcan A., Emer O., Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med 2012, 23(2):165-168.